Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.46 |
| ▸ | GRM5 | P41594 | 9/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23580352 | 1.00 | GRM1 (0.46) | GRM1GRM5PDK4NAMPTSMARCA2 | |
| SCHEMBL23581043 | 0.84 | NAMPT (0.44) | GRM1GRM5PDK4NAMPTCNR1 | |
| SCHEMBL30340778 | 0.84 | NAMPT (0.44) | GRM1GRM5PDK4NAMPTCNR1 | |
| SCHEMBL23581048 | 0.80 | SMARCA2 (0.49) | NAMPTSMARCA2SMARCA4PBRM1 | |
| SCHEMBL30340771 | 0.80 | SMARCA2 (0.49) | NAMPTSMARCA2SMARCA4PBRM1 | |
| SCHEMBL23580367 | 0.78 | NAMPT (0.47) | GRM1GRM5PDK4NAMPTSMARCA2 | |
| SCHEMBL30178737 | 0.78 | NAMPT (0.47) | GRM1GRM5PDK4NAMPTSMARCA2 | |
| SCHEMBL31548741 | 0.77 | SMARCA2 (0.62) | GRM1GRM5PDK4NAMPTSMARCA2 | |
| SCHEMBL22777343 | 0.77 | PDK4 (0.52) | GRM1GRM5PDK4NAMPTSMARCA2 | |
| SCHEMBL29910459 | 0.76 | SMARCA2 (0.66) | GRM1GRM5PDK4NAMPTSMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569485-B2 | SMARCA inhibitors and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | GRM1 4369/4885GRM5 4470/4885PDK4 3434/4885 |
| US-12569485-B2 | SMARCA inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA2 | GRM1 3471/4885GRM5 4436/4885PDK4 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.